Drug Approval | August 27, 2021
Indoco’s AnaCipher receives UK-MHRA accreditation
The clinical research organisation located in Hyderabad is a USFDA inspected facility
The clinical research organisation located in Hyderabad is a USFDA inspected facility
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
The submission to the US FDA has been initiated and they intend to file these data with the European Medicines Agency and other regulatory bodies in the coming weeks
The company to receive upfront and milestone payments, in addition to royalties
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
It is the first branded generic alternative to Fostair 100/6 pMDI
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
Subscribe To Our Newsletter & Stay Updated
